SCHEMBL19902364

SCHEMBL19902364

O=C(N[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1)c1cc2nccnc2s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.44
NPC1 O15118 6/20 0.44
KMT2A Q03164 1/20 0.44
CCNA2 P20248 1/20 0.44
CDK2 P24941 1/20 0.44
KDR P35968 1/20 0.44
PLK1 P53350 1/20 0.44
CCNA1 P78396 1/20 0.44
MAPK1 P28482 3/20 0.42
DCLK1 O15075 1/20 0.42
PDPK1 O15530 1/20 0.42
PRKD3 O94806 1/20 0.42
MAP4K4 O95819 1/20 0.42
CHEK2 O96017 1/20 0.42
PIM1 P11309 1/20 0.42
AXL P30530 1/20 0.42
FLT4 P35916 1/20 0.42
FLT3 P36888 1/20 0.42
MAPK9 P45984 1/20 0.42
CSNK1D P48730 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17452845 0.88 ROCK2 (0.53) RAB9ANPC1KMT2ACCNA2CDK2
SCHEMBL19902484 0.78 CHRNA7 (0.46) RAB9ANPC1KMT2ACCNA2CDK2
SCHEMBL19902689 0.75 ROCK2 (0.46) RAB9ANPC1KMT2AAURKBROCK2
SCHEMBL19902356 0.75 CHRNA7 (0.45) RAB9ANPC1ROCK2ROCK1MAPK8
SCHEMBL19902628 0.74 RIPK1 (0.48) NPC1KMT2AROCK2ROCK1MAPK8
SCHEMBL19902690 0.74 SMN1; SMN2 (0.44) RAB9ANPC1KMT2AMAPK9AURKB
SCHEMBL19902696 0.74 NPC1 (0.50) RAB9ANPC1KMT2AROCK2L3MBTL1
SCHEMBL20229652 0.74 ROCK2 (0.41) RAB9ANPC1ROCK2L3MBTL1ROCK1
SCHEMBL19902631 0.73 HDAC8 (0.42) RAB9ANPC1ROCK2ROCK1HTT
SCHEMBL19902458 0.73 SCN4A (0.48) NPC1KMT2AROCK2MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 RAB9A 564/4885NPC1 2709/4885KMT2A 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.